And then secondly, on the topic of partnerships and business development. I mean going forward, what would you be looking for in your next set of partnerships? What kind of capabilities would be most additive to seek out? And conversely, what also do you think you could be bringing your partners with the next set of partnerships that you weren't able to with the earlier set of partnerships? Thanks. Andrew Hopkins Sure. Thanks, Andrew, and thanks, Vikram. So the time lines we put out the time from starting t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 13(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Exscientia Business and Financial Update for the Full Year 2022 OXFORD, U.K. - Exscientia plc (Nasdaq: EXAI) Recent developments in the Company's pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below. Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a.m. EDT. "2022 was marked by significant milestones for Exscientia, including signing a groundbreaking strategic collaboration with Sanofi, as we cont ...

Timeline for illustrative purposes EXS74539 ('539) (LSD1 inhibitor) • LSD1 demethylates histones, playing a critical role in suppressing the expression of genes required for cellular differentiation • Drives the proliferation and survival of several tumour types • LSD1 is overexpressed in many cancer types across haematology and oncology • Inhibiting LSD1 reactivates expression of genes driving differentiation; can inhibit cell growth and sensitise any remaining cells to other agents A brain penetrant LSD1 ...

Exscientia plc (NASDAQ:EXAI) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Sara Sherman - Vice President-Investor Relations Andrew Hopkins - Chief Executive Officer & Executive Director Ben Taylor - Chief Financial Officer & Chief Strategy Officer Dave Hallett - Chief Operating Officer Mike Krams - Chief Quantitative Medicine Officer Garry Pairaudeau - Chief Technology Officer Conference Call Participants Michael Ryskin - Bank of America Operator Hello, everyone. My name ...

✈ Exscientia 3Q 2022 Business Update November 15, 2022 Forward-looking statements This presentation and accompanying oral presentation (referred to herein collectively as the "presentation") contain express and implied forwardlooking statements that involve substantial risks and uncertainties. All statements contained in this presentation, other than statements of historical facts, including statements regarding expectations of Exscientia plc ("we," "us", "our," or "Exscientia"), our strategy, future operat ...

Exscientia plc (NASDAQ:EXAI) Q2 2022 Earnings Conference Call August 18, 2022 8:30 AM ET Company Participants Sara Sherman - VP, IR Andrew L. Hopkins - Founder and CEO Ben R. Taylor - CFO and Chief Strategy Officer Richard Law - Chief Business Officer David Hallett - COO Garry Pairaudeau - CTO Conference Call Participants Michael Ryskin - Bank of America Merrill Lynch Vikram Purohit - Morgan Stanley Chris Shibutani - Goldman Sachs Group, Inc. Peter Lawson - Barclays Bank PLC Operator Hello, everyone. My nam ...

Exscientia plc (NASDAQ:EXAI) Q1 2022 Earnings Conference Call May 26, 2022 8:30 AM ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Nikolaus Krall - Vice President of Precision Medicine Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Officer Conference Call Participants Chris Shibutani - Goldman Sachs Group, Inc. Peter Lawson - Barclays Bank PLC Vikram Purohit - Morgan Stanley Michael Ryskin - ...

� Exscientia Exscientia Technology in Focus March 24, 2022 Safe Harbor Statement This presentation and accompanying oral presentation (referred to herein collectively as the "presentation") contain express and implied forward-looking statements that involve substantial risks and uncertainties. All statements contained in this presentation, other than statements of historical facts, including statements regarding expectations of Exscientia plc ("we," "us", "our," or "Exscientia"), our strategy, future operat ...

Exscientia plc (NASDAQ:EXAI) Q4 2021 Earnings Conference Call March 24, 2022 8:30 AM ET Corporate Participants Sara Sherman - Vice President, Investor Relations Andrew Hopkins - Chief Executive Officer Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Officer Garry Pairaudeau - Chief Technology Officer Conference Call Participants Michael Ryskin - Bank of America Peter Lawson - Barclays Vikram Purohit - Morgan Stanley Operator Hello, everyone. My name is Chris a ...